Review articlePublished 30 May 2023

Docetaxel resistance in prostate cancer

Authors: Shinu Ozaki

Archives in Cancer Research

Volume 11 · Issue 3 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Prostate cancer is one of the most common malignant tumours in the world, and it can occur as a result of genetic mutations and their accumulation when the tumour progresses to an advanced stage. Because of the absence of distinct symptoms in the early stages of prostate cancer, most cancer patients are discovered at advanced stages where tumour cells respond poorly to chemotherapy. Furthermore, genetic alterations in prostate cancer increase tumour cell aggressiveness. Docetaxel and paclitaxel are well-known drugs for prostate tumour treatment, and they have a similar role in cancer therapy that is based on preventing depolymerization of microtubules, disrupting microtubule equilibrium, and causing a delay in cell cycle progression. The current review seeks to provide insight on the mechanisms behind paclitaxel and docetaxel resistance in prostate cancer. When oncogenic factors such as CD133 are upregulated and PTEN, a tumour suppressor, is downregulated, prostate tumour cells become more malignant and can develop medication resistance. Furthermore, phytochemicals have been used as anti-tumor agents to reduce chemoresistance in prostate cancer. Naringenin and lovastatin are two anti-tumor drugs that have been utilised to slow the development of prostate cancer and improve treatment sensitivity. Furthermore, nanostructures like polymeric micelles and nanobubbles have been used to deliver anti-tumor drugs while reducing the danger of chemoresistance development. The current review highlights these topics in order to bring fresh insight on reversing treatment resistance in prostate cancer. Keywords Prostate cancer, Paclitaxel, Docetaxel, Chemoresistance, Targeted delivery, Nanoparticles

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalArchives in Cancer Research
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Shinu Ozaki”